Xarelto is not currently expected to go generic in the USA in 2025. The patent for the original innovator drug, manufactured by Bayer and Janssen, is set to expire in 2028 [1].
When does Xarelto's main patent expire?
The primary patent protecting Xarelto (rivaroxaban) is scheduled to expire in 2028. This means that generic versions of the drug could potentially become available in the United States from that point forward [1].
Are there other patents or exclusivity periods for Xarelto?
While the main patent is a significant factor, drug exclusivity can be influenced by various other patents, including those for specific formulations, manufacturing processes, or new uses. These can sometimes extend market protection beyond the core patent expiry. Information on the full landscape of Xarelto's patent and exclusivity can be found on DrugPatentWatch.com [2].
What are the implications of generic Xarelto becoming available?
The introduction of generic versions of Xarelto would likely lead to lower drug prices for patients and healthcare systems. Generic drugs are typically bioequivalent to their brand-name counterparts but are manufactured by different companies and sold at a lower cost once patent protections have expired [3].
Who manufactures Xarelto?
Xarelto was developed and is primarily marketed by Bayer and Janssen Pharmaceuticals [1]. When generic versions become available, other pharmaceutical companies will likely manufacture and distribute them.
How do generics get approved in the USA?
In the United States, generic drugs are approved by the Food and Drug Administration (FDA). For a generic drug to be approved, it must demonstrate that it is bioequivalent to the brand-name drug, meaning it contains the same active ingredient and works in the same way in the body [3].